Nick Thomas-Symonds MP: speeches

Speeches

• 14 Apr 2026 · Infected Blood Compensation Scheme · Hansard source

  More

  I am grateful to the hon. Gentleman and his party for the tone that they have taken throughout this process, and I welcome the opportunity to continue to work on a cross-party basis, because that is important. Like him, I have had that discussion with the charities—including the Hepatitis C Trust, as it happens—and I very much understand the case they make about multi-year funding as opposed to single-year funding. The funding comes from the Department of Health and Social Care, rather than from me, but I will certainly write to the relevant Minister to raise that point. The introduction of level 2B banding for interferon treatment is important, because of the specific, awful effects of multiple rounds of interferon treatment. On the two points that the hon. Gentleman has specifically raised, I will ensure that he gets a detailed answer in writing.

• 14 Apr 2026 · Infected Blood Compensation Scheme · Hansard source

  More

  With permission, I will update the House on the Government’s response to the recommendations of the infected blood inquiry’s additional report. I will start by updating the House on the delivery of compensation by the Infected Blood Compensation Authority—or IBCA, as we refer to it. As of 7 April, 3,273 people have received an offer and over £2 billion has now been paid out. That includes the first payments to all eligible groups. I am sure that Members across the whole House will welcome that progress. In July last year, the infected blood inquiry published its additional report, which made recommendations for both the Government and IBCA. Part of our response to that report was a public consultation on changes to the infected blood compensation scheme. I am here today to update the House on the outcome of that consultation. First, I should say that I am deeply grateful to everyone who responded and provided deeply personal stories. They must be at the heart of the decisions that the Government make, just as they were throughout the work of the inquiry. The consultation was vital for engaging the community on our proposals. The Government have also sought advice from the infected blood compensation scheme technical expert group. Alongside the consultation response, today I am publishing the group’s final report, which sets out its advice to the Government and amendments to the compensation scheme. To inform that advice, the technical expert group conducted roundtable discussions with community representatives on specific aspects of the scheme, and that was separate to the consultation. For transparency, I am also publishing the minutes of the roundtable discussions, the group’s own meetings and a summary of written responses to the roundtables. Let me turn to the changes to the scheme. Today the Government have published our full response to the consultation, and that sets out how the scheme will now change. Before I lay out each change in detail, let me explain the overall package. The community was clear that the scheme must do more to recognise people’s individual experiences and compensate them fairly in a way that minimises the administrative burden placed on those who have been harmed, minimises the demand for evidence and maintains the delivery of tariff-based compensation. Those requirements underpin the changes. For infected people, the changes will increase the amount of core compensation available and increase the options available for supplementary compensation awards. For affected people, additional core compensation will be available to those eligible. We consulted on seven specific areas, and we are making substantive changes in all seven. In four areas, we are actually going further than our original proposal. Let me turn first to the special category mechanism. We will introduce a new supplementary award to give additional compensation to people who have been assessed as eligible for the SCM or who can now demonstrate to IBCA that they meet the criteria. After considering the community’s views, we will ensure that every eligible person has this award backdated to 2017, because that is when the special category mechanism was first introduced. Many of those infected suffered from terrible mental health issues as a result of their infection, as we heard in their testimonies. We will amend the scheme so that the new SCM supplementary award gives people additional compensation where the psychological harm that they experienced means that the core route compensation simply does not go far enough. We believe that this will result in more comprehensive recognition of the mental health issues caused by infected blood and the resulting years of harm. The inquiry recommended that we change the core route’s severity bandings to recognise the harms caused to infected people by interferon treatment, and proposed a new “level 2B” severity banding for those who receive this treatment. We accept that change is necessary, and we will introduce this new severity band to increase people’s injury, financial loss and care awards. In addition, if someone has had multiple rounds of interferon treatment, they will be compensated for each round. The inquiry recommended changes to the calculation of past financial loss and past care awards for those who choose to continue receiving support scheme payments. We will remove the 25% deduction applied to past care compensation, as was recommended by the inquiry. The consultation also set out two options for how financial loss could be calculated for those who continue to receive support scheme payments: the way the scheme currently does it, and an alternative. Because of the range of views on which was best, we will ensure that people receive past financial loss compensation based on whichever of the two calculations presented is most financially beneficial for them. The inquiry asked the Government to look at the evidence requirements for the exceptional loss award. We were keen to hear the community’s views on that in order to develop a way forward that avoided lengthy, individualised assessments of people’s circumstances. We will ensure that all forms of evidence of actual earnings can be considered by IBCA. We will also make additional compensation available to infected people who lack evidence of earnings but who had clear potential to earn more than average. We will offer a £60,000 lump sum on top of people’s core awards to those who can show they either had a job offer or recently started a job where the salary was higher than the median salary but had their progress impeded by their infection. Through the consultation, we also heard about the experiences of affected people and the particular harms they suffered. We will increase the core injury award for several groups of affected people, including bereaved parents whose child sadly died before they turned 18, bereaved partners, and children and siblings affected under the age of 18. Those changes will give more compensation to affected people whose particular experience of the scandal was undoubtedly profound and deeply harmful. The awards will form part of the core award, and they will not require additional evidence from applicants. I know that the matter of unethical research is of particular concern to Members across the House. It is one of the most shocking aspects of the scandal. We heard that the existing approach may not have compensated everyone who suffered that wrongdoing. We have therefore changed the scope of the award so that anyone treated in the UK for a bleeding disorder in 1985 or earlier will receive further compensation. It was also clear from the consultation responses that the amount offered does not reflect the harm done. I say today to the House that we will increase the unethical research awards. That includes increasing the £25,000 for those who attended Treloar’s school to £60,000 as well as introducing a new unethical research award for those treated elsewhere for a bleeding disorder during childhood at a rate of £45,000. We are also tripling the award for those treated for a bleeding disorder in adulthood to £30,000. I have touched on all seven of the areas we directly addressed in the consultation; of course, I encourage hon. Members across the House to read the full response that is being published. The consultation also invited respondents to raise any other concerns they had about the design of the scheme. One of the most compelling things we heard was that the scheme does not sufficiently recognise the profound impact of infection during childhood. We have heard the community clearly on that, so we will make a further change to the compensation scheme to address it: we will introduce a 50% increase to the core autonomy award for people who were infected at age 18 or under. Official Report , 25 June 2026; Vol. 788, c. 2WC. (Correction). I hope those changes go some way to showing our commitment to listening to the community and making decisions, with those impacted at the forefront of our minds. In order to make those substantial changes to the scheme, we will bring forward further legislation in due course. While the consultation provided one way for the community to offer feedback, the inquiry recommended there be an identified way for concerns to be considered. Today, I am pleased to launch a new mechanism that builds on existing engagement and feedback channels through which people can raise concerns about the function of the infected blood compensation scheme with the Cabinet Office and with IBCA. Both organisations will then publish quarterly summaries of feedback received on the scheme’s design and delivery, and any action being taken as a result. I expect the first of those summaries to be published in early July. The findings of the inquiry must be met with tangible, systemic change. I hope that what I have set out goes some way towards showing our commitment to enacting this change. I pay tribute to Sir Brian Langstaff, his team and everyone who gave testimony to the inquiry for ensuring that that human element of this tragedy remains a focal point of the inquiry’s work. The compensation scheme’s most basic purpose is to provide financial recognition of the losses and harms faced by victims, both infected and affected. Beyond that, it must reflect and embody their stories if it is to truly deliver justice, not just for those we tragically lost, but for those who continue to fight. I commend this statement to the House.

• 3 Dec 2025 · Draft Infected Blood Compensation Scheme (Amendment) Regulations 2025 · Hansard source

  More

  I beg to move, That the Committee has considered the draft Infected Blood Compensation Scheme (Amendment) Regulations 2025. It is a pleasure to serve under you for the first time in your new elevated capacity as Chair, Dr Murrison. Since the publication of the infected blood inquiry’s detailed report in May 2024, the Government have worked to establish a compensation scheme and to set up the Infected Blood Compensation Authority, known as IBCA, to deliver it. I can tell the Committee that since the compensation scheme opened last year, IBCA has contacted all infected people registered with a support scheme to start their claim and made offers of more than £2 billion. It has now opened the service to the first claims from living infected people who have never been compensated. I am pleased with this progress, which is a significant step in the right direction towards delivering justice to those impacted, with IBCA now moving towards opening the service for those affected and for the estates of deceased infected people. Colleagues may be aware that I, my right hon. Friend the Secretary of State for Health and Social Care and the shadow Secretary of State for Health and Social Care, the right hon. Member for Daventry (Stuart Andrew), among others, spoke at the World AIDS Day event hosted by the Terrence Higgins Trust in Speaker’s House on Monday. It was important that the Government marked that important day. I am proud to say that IBCA has made offers to over 90% of those infected with HIV who are registered with a support scheme, and it hopes to have made offers to the remaining eligible living HIV claimants by the end of this year. In July, the infected blood inquiry published its additional report, which made 15 recommendations to the Government on the design of the scheme. I immediately accepted seven of those recommendations, and the regulations we are considering today will implement the five that require legislation to achieve. The remaining eight recommendations are subject to an ongoing public consultation, as per Sir Brian Langstaff’s recommendation, and the Government expect to bring in further legislation next year to implement the changes we will need following that consultation. Listening to the voices of the community is essential. That is why, in the Budget last week, the Chancellor announced changes that will ensure that infected blood compensation payments are relieved from inheritance tax in cases where the original infected or affected person eligible for compensation has died before the compensation is paid. I am pleased that we have been able to make that change; it is something that was raised with me by Members across the House when I last made a statement, and it is really important that justice is not only delivered, but reflected in the way the compensation is treated. Turning to the regulations at hand, I will set out the changes we are proposing to the scheme in direct response to the inquiry’s recommendations. Regulation 3 responds to the inquiry’s recommendation 3(a) by removing the 1982 start date for eligible HIV infections, meaning that anyone who was infected with HIV via infected blood or infected blood products before 1 November 1985 will be eligible for the scheme. Regulation 4 makes changes in line with the inquiry’s recommendation 8(b) on affected estates. Its additional report sets out that the time being taken to deliver compensation is disadvantageous to affected people who are older or are in ill health. The inquiry recommended that where an affected person has sadly passed away during a specified date range, their compensation should become part of their estate. The Government have not only accepted this recommendation but gone beyond it, extending the recommended date range by two additional years, to be between 21 May 2024 and 31 March 2031. Regulation 6 actions the inquiry’s recommendation 4(e), which recommends that the Government remove the need for applicants with hepatitis C or B to evidence their date of diagnosis. The date of diagnosis does not have a bearing on the calculation of an individual’s compensation. Therefore, making this change removes an unnecessary burden and will allow swifter processing of claims by IBCA. Regulation 7 implements the inquiry’s recommend-ation 4(d), which relates to how the scheme deems the level of severity of someone’s hepatitis infection. Where somebody shows a level 4 diagnosis of hepatitis, but no level 3 diagnosis, we are amending the scheme so that they are deemed to have spent six years at level 3 prior to the level 4 diagnosis. That will uplift the overall compensation package; it is also a recognition that the burden of evidence shall not fall on the claimant, which is of crucial importance, particularly in light of Sir Brian Langstaff’s original finding about lost medical records. We have heard from the community and the inquiry that the use of effective treatment dates under the scheme does not reflect the lived experience of many victims as not all infected people were able to resume work after treatment for various reasons, including continued illness or stigma, and that some people received effective treatment much later than it was introduced. In line with the inquiry’s recommendation 4(c), regulation 9 rectifies that by removing the earnings floor on the exceptional loss award for financial loss supplementary route. There is therefore a route available for infected people to present evidence on their actual earning loss. The Government also recognise that concerns have been raised about bereaved partners’ access to support scheme payments following the tragic loss of their spouse. In response to that and to the inquiry’s recommendation 9(a), the Government reopened bereaved partner applications to the infected blood support scheme on 22 October. I should place on record my thanks to colleagues in the devolved Administrations for working with us to ensure that we could achieve this quickly. One of the key themes of the inquiry’s additional report was the need for IBCA to increase the speed at which it delivers compensation. In order to achieve that, regulation 10 delays by one calendar year the transfer of responsibility to make support scheme payments from IBSS to IBCA. That has been done to allow IBCA to focus its resources on continuing to build an effective compensation scheme. Again, I am very grateful to the devolved Administrations for their collaborative work on making that happen. Outside the inquiry’s report, regulation 14 makes a number of technical changes to ensure that the compensation scheme functions correctly and that its administration is improved. They are minor corrections that do not impact overall policy. This compensation scheme is for people who have had their lives changed by unimaginable pain and suffering. These regulations are a direct response to those people’s calls for change that meets their expectations of this Government and carry forward a sense of justice. As Members of the House of Commons, we all share the sentiment that the victims of this scandal should be at the heart of this work. I believe that the regulations are a significant step in ensuring that the compensation scheme delivers for those impacted and I commend them to the Committee.

• 30 Oct 2025 · Infected Blood Compensation Scheme · Hansard source

  More

  My hon. Friend raises a really important issue, because charities have played an absolutely vital role in supporting and advocating for the victims of this scandal. Money was already allocated in this financial year. I know that there are concerns going forward. He can be assured that I will work closely with Health and Social Care Ministers on that.

• 30 Oct 2025 · Infected Blood Compensation Scheme · Hansard source

  More

  I pay tribute to my hon. Friend’s work with the all-party parliamentary group. On the first question, the compensation that has been received clearly is exempt from tax. I understand exactly the point he is making about someone, such as a widow, who inherits or has the compensation on behalf of a deceased partner. That money will be received tax-free, but I appreciate his point about the speed that is needed, because of the age of so many of the victims of this scandal. That is through no fault of their own, but is the fault of the state. The tax exemption is in line with the policy that is pursued consistently across Government. On his second point about the campaigning groups, I am conscious that we are approaching the end of another tax year. I pay tribute to the work that the charities do, and I undertake to him that I will take up that matter with the Department of Health and Social Care.